Jason Amello - 21 Sep 2022 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Financial Officer
Signature
/s/ Jason A. Amello
Issuer symbol
CADL
Transactions as of
21 Sep 2022
Net transactions value
$0
Form type
4
Filing time
23 Sep 2022, 16:15:13 UTC
Previous filing
19 Jan 2022
Next filing
30 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Stock Option (Right to Buy) Award $0 +230,000 $0.000000 230,000 21 Sep 2022 Common Stock 230,000 $3.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on September 21, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.